187.78
price down icon0.12%   -0.22
after-market  After Hours:  187.78 
loading
Penumbra Inc stock is currently priced at $187.78, with a 24-hour trading volume of 195.54K. It has seen a -0.12% decreased in the last 24 hours and a -10.04% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $188.9 pivot point. If it approaches the $185.7 support level, significant changes may occur.
Previous Close:
$188.00
Open:
$187.47
24h Volume:
195.54K
Market Cap:
$7.28B
Revenue:
$1.10B
Net Income/Loss:
$93.39M
P/E Ratio:
182.31
EPS:
1.03
Net Cash Flow:
$105.36M
1W Performance:
-0.62%
1M Performance:
-10.04%
6M Performance:
-25.73%
1Y Performance:
-44.37%
1D Range:
Value
$185.09
$188.47
52W Range:
Value
$180.93
$348.67

Penumbra Inc Stock (PEN) Company Profile

Name
Name
Penumbra Inc
Name
Phone
510-748-3200
Name
Address
1321 Harbor Bay Parkway, Alameda, CA
Name
Employee
1,700
Name
Twitter
@penumbrainc
Name
Next Earnings Date
2024-06-06
Name
Latest SEC Filings
Name
PEN's Discussions on Twitter

Penumbra Inc Stock (PEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-06-23 Initiated Morgan Stanley Equal-Weight
Jul-19-23 Initiated Robert W. Baird Outperform
Mar-29-23 Downgrade Needham Buy → Hold
Jan-30-23 Initiated Piper Sandler Overweight
Nov-04-22 Upgrade Citigroup Neutral → Buy
Oct-12-22 Initiated Jefferies Buy
Oct-05-22 Downgrade Citigroup Buy → Neutral
Sep-09-22 Upgrade Needham Hold → Buy
Jul-18-22 Initiated RBC Capital Mkts Outperform
Apr-19-22 Initiated Deutsche Bank Buy
Mar-08-22 Initiated Needham Hold
Sep-16-21 Initiated Truist Buy
Jun-04-21 Upgrade BTIG Research Neutral → Buy
Dec-16-20 Downgrade BTIG Research Buy → Neutral
Oct-07-20 Resumed Canaccord Genuity Buy
Sep-29-20 Initiated BTIG Research Buy
Sep-08-20 Downgrade BofA Securities Buy → Neutral
Mar-05-20 Initiated Citigroup Buy
Jun-13-19 Reiterated BofA/Merrill Buy
May-30-19 Upgrade JP Morgan Neutral → Overweight
May-21-19 Initiated William Blair Outperform
Oct-29-18 Resumed BofA/Merrill Buy
Oct-08-18 Initiated RBC Capital Mkts Outperform
Feb-21-18 Initiated William Blair Outperform
Jan-02-18 Downgrade JP Morgan Overweight → Neutral
Nov-30-15 Reiterated Canaccord Genuity Buy
Oct-13-15 Initiated Wells Fargo Outperform
View All

Penumbra Inc Stock (PEN) Financials Data

Penumbra Inc (PEN) Revenue 2024

PEN reported a revenue (TTM) of $1.10 billion for the quarter ending March 31, 2024, a +23.87% rise year-over-year.
loading

Penumbra Inc (PEN) Net Income 2024

PEN net income (TTM) was $93.39 million for the quarter ending March 31, 2024, a +1,341% increase year-over-year.
loading

Penumbra Inc (PEN) Cash Flow 2024

PEN recorded a free cash flow (TTM) of $105.36 million for the quarter ending March 31, 2024, a +287.29% increase year-over-year.
loading

Penumbra Inc (PEN) Earnings per Share 2024

PEN earnings per share (TTM) was $2.37 for the quarter ending March 31, 2024, a +1,381% growth year-over-year.
loading
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
$256.01
price down icon 5.63%
medical_devices STE
$218.29
price down icon 1.25%
medical_devices ZBH
$107.19
price up icon 0.21%
medical_devices PHG
$25.69
price down icon 0.85%
$115.95
price up icon 1.88%
medical_devices EW
$87.29
price down icon 0.43%
Cap:     |  Volume (24h):